4

Changes in Ownership

Iambic Therapeutics, Inc. Filed 2026-10-19 Acc 0002151678-26-000007

Director bought 718,750 shares at $16.00 ($11,500,000)

Director acquired 1,927,252 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Insider	Date	Transaction	Shares	Price	Value	Owned after	D/I
Rachlin Evan Lockwood Director	2026-10-16	Conversion	+1,458,736			1,458,736	I
Rachlin Evan Lockwood Director	2026-10-16	Conversion	+410,762			1,869,498	I
Rachlin Evan Lockwood Director	2026-10-16	Purchase	+718,750	$16.00	$11,500,000	2,588,248	I
Rachlin Evan Lockwood Director	2026-10-16	Conversion	+57,754			57,754	I
Derivatives
Rachlin Evan Lockwood Director	2026-10-16	Conversion · Series B Convertible Preferred Stock	−1,152,025			0	I
Rachlin Evan Lockwood Director	2026-10-16	Conversion · Series B Convertible Preferred Stock	−57,754			0	I
Rachlin Evan Lockwood Director	2026-10-16	Conversion · Series B-3 Convertible Preferred Stock	−306,711			0	I
Rachlin Evan Lockwood Director	2026-10-16	Conversion · Convertible Promissory Notes	−410,762			0	I
Open-market purchases · 718,750 sh · avg $16.00 · $11,500,000